Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2

Until today effective antivirals for COVID-19 treatment are not widely available. Here, Zhao et al. characterize a dual-functional cross-linking peptide, 8P9R, that can inhibit SARS-CoV-2 virus entry in vitro and suppresses viral replication in vivo in golden Syrian hamster.

Guardado en:

Detalles Bibliográficos
Autores principales:	Hanjun Zhao, Kelvin K. W. To, Hoiyan Lam, Xinxin Zhou, Jasper Fuk-Woo Chan, Zheng Peng, Andrew C. Y. Lee, Jianpiao Cai, Wan-Mui Chan, Jonathan Daniel Ip, Chris Chung-Sing Chan, Man Lung Yeung, Anna Jinxia Zhang, Allen Wing Ho Chu, Shibo Jiang, Kwok-Yung Yuen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/7afe365d9513460da362a27eacf0cb49
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7afe365d9513460da362a27eacf0cb49
record_format	dspace
spelling	oai:doaj.org-article:7afe365d9513460da362a27eacf0cb492021-12-02T13:33:01ZCross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-210.1038/s41467-021-21825-w2041-1723https://doaj.org/article/7afe365d9513460da362a27eacf0cb492021-03-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-21825-whttps://doaj.org/toc/2041-1723Until today effective antivirals for COVID-19 treatment are not widely available. Here, Zhao et al. characterize a dual-functional cross-linking peptide, 8P9R, that can inhibit SARS-CoV-2 virus entry in vitro and suppresses viral replication in vivo in golden Syrian hamster.Hanjun ZhaoKelvin K. W. ToHoiyan LamXinxin ZhouJasper Fuk-Woo ChanZheng PengAndrew C. Y. LeeJianpiao CaiWan-Mui ChanJonathan Daniel IpChris Chung-Sing ChanMan Lung YeungAnna Jinxia ZhangAllen Wing Ho ChuShibo JiangKwok-Yung YuenNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Hanjun Zhao Kelvin K. W. To Hoiyan Lam Xinxin Zhou Jasper Fuk-Woo Chan Zheng Peng Andrew C. Y. Lee Jianpiao Cai Wan-Mui Chan Jonathan Daniel Ip Chris Chung-Sing Chan Man Lung Yeung Anna Jinxia Zhang Allen Wing Ho Chu Shibo Jiang Kwok-Yung Yuen Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
description	Until today effective antivirals for COVID-19 treatment are not widely available. Here, Zhao et al. characterize a dual-functional cross-linking peptide, 8P9R, that can inhibit SARS-CoV-2 virus entry in vitro and suppresses viral replication in vivo in golden Syrian hamster.
format	article
author	Hanjun Zhao Kelvin K. W. To Hoiyan Lam Xinxin Zhou Jasper Fuk-Woo Chan Zheng Peng Andrew C. Y. Lee Jianpiao Cai Wan-Mui Chan Jonathan Daniel Ip Chris Chung-Sing Chan Man Lung Yeung Anna Jinxia Zhang Allen Wing Ho Chu Shibo Jiang Kwok-Yung Yuen
author_facet	Hanjun Zhao Kelvin K. W. To Hoiyan Lam Xinxin Zhou Jasper Fuk-Woo Chan Zheng Peng Andrew C. Y. Lee Jianpiao Cai Wan-Mui Chan Jonathan Daniel Ip Chris Chung-Sing Chan Man Lung Yeung Anna Jinxia Zhang Allen Wing Ho Chu Shibo Jiang Kwok-Yung Yuen
author_sort	Hanjun Zhao
title	Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
title_short	Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
title_full	Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
title_fullStr	Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
title_full_unstemmed	Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
title_sort	cross-linking peptide and repurposed drugs inhibit both entry pathways of sars-cov-2
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7afe365d9513460da362a27eacf0cb49
work_keys_str_mv	AT hanjunzhao crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT kelvinkwto crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT hoiyanlam crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT xinxinzhou crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT jasperfukwoochan crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT zhengpeng crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT andrewcylee crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT jianpiaocai crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT wanmuichan crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT jonathandanielip crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT chrischungsingchan crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT manlungyeung crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT annajinxiazhang crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT allenwinghochu crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT shibojiang crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2 AT kwokyungyuen crosslinkingpeptideandrepurposeddrugsinhibitbothentrypathwaysofsarscov2
_version_	1718392862949769216

Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2

Ejemplares similares